Supreme Court Orders Committee To Examine Pharma Freebies To Doctors For Prescribing Drugs
The Supreme Court on Thursday directed the Union government to constitute a committee to examine the issue of pharmaceutical companies offering gifts, incentives and other benefits to doctors to promote the prescription of their medicines.
A Bench comprising Justices Vikram Nath and Sandeep Mehta passed the direction while hearing a public interest litigation seeking stronger and legally enforceable regulation of pharmaceutical marketing practices.
The petition was filed by the Federation of Medical and Sales Representatives Associations of India and others. It raises concerns that pharmaceutical companies may use expensive gifts, hospitality, travel facilities and other incentives to influence doctors’ prescribing decisions.
The petitioners have argued that such practices can result in doctors being influenced by commercial considerations while prescribing medicines, potentially increasing the use of expensive or unnecessary drugs.
The Supreme Court has now directed the Centre to constitute a three-member committee to examine the issue and consider the suggestions and representations made by stakeholders.
The committee will make recommendations to the Union government on whether a statutory framework is required to regulate pharmaceutical companies and their marketing practices.
The issue has been under judicial consideration for several years. The petitioners have argued that the existing regulatory system is largely voluntary and does not provide an effective statutory mechanism to hold pharmaceutical companies accountable for offering inducements to doctors.
The Centre, meanwhile, has pointed to the existing Uniform Code for Pharmaceutical Marketing Practices, or UCPMP, which contains restrictions on gifts, hospitality, travel facilities and monetary benefits offered by pharmaceutical companies to healthcare professionals.
However, the proceedings have highlighted a perceived regulatory gap. While medical professionals can face disciplinary consequences for accepting certain benefits, questions remain over the extent to which pharmaceutical companies themselves can be subjected to legally enforceable penalties for offering such incentives.
The Centre had earlier informed the Supreme Court that discussions had taken place between the Department of Pharmaceuticals, the Department of Health and Family Welfare and the Department of Legal Affairs on the need for stronger regulation.
The government proposed the three-member committee after considering whether the existing framework should be given statutory backing.
The petitioners opposed the need for another committee, pointing out that the government had previously constituted a high-level committee in 2022 to examine the issue.
That earlier exercise had considered whether the voluntary regulatory mechanism should be replaced with a legally binding framework. The petitioners have maintained that the problem requires concrete statutory action rather than another round of deliberations.
The Supreme Court has also referred to its earlier judgment in Apex Laboratories Pvt. Ltd. v. Deputy Commissioner of Income Tax, decided in 2022.
In that case, the court had examined pharmaceutical companies providing freebies to doctors and held that such benefits could not be claimed as business expenditure for tax purposes when they were prohibited by law.
The earlier judgment had also recognised the special relationship between doctors and patients and the potential consequences when commercial incentives influence medical decisions.
The present proceedings go beyond the tax question and examine whether pharmaceutical companies should be subject to a comprehensive statutory framework governing their interactions with doctors.
The existing UCPMP contains provisions concerning gifts, physician samples, continuing medical education and other promotional activities. It also provides mechanisms for handling complaints and reviewing alleged violations.
The Supreme Court’s latest direction will now require the proposed committee to examine whether these mechanisms are sufficient or whether stronger legislation with enforceable penalties is necessary.
The issue has implications for both medical professionals and patients. The central concern is whether promotional incentives offered by pharmaceutical companies can compromise the independence of prescribing decisions and contribute to unnecessary or costly medication.
The petitioners have also linked the issue to the constitutional right to health, arguing that unethical pharmaceutical marketing can ultimately affect patients through higher treatment costs and inappropriate prescriptions.
The Supreme Court has directed the Centre to place a compliance affidavit before it explaining the steps taken to constitute the committee and proceed with the exercise.
The matter has been listed for January 29, 2027, when the court will consider the Centre’s compliance.
The latest order does not itself impose a new statutory ban on pharmaceutical freebies. Instead, it begins a structured examination of whether the existing regulatory framework should be strengthened through legislation.
The committee’s recommendations could therefore become an important step in determining how pharmaceutical companies are permitted to market medicines and interact with doctors in India, particularly where gifts or other financial and non-financial incentives are involved.
